ATE407676T1 - Topoisomerasehemmern zur behandlung von chirurgischen verklebungen - Google Patents

Topoisomerasehemmern zur behandlung von chirurgischen verklebungen

Info

Publication number
ATE407676T1
ATE407676T1 AT01909384T AT01909384T ATE407676T1 AT E407676 T1 ATE407676 T1 AT E407676T1 AT 01909384 T AT01909384 T AT 01909384T AT 01909384 T AT01909384 T AT 01909384T AT E407676 T1 ATE407676 T1 AT E407676T1
Authority
AT
Austria
Prior art keywords
topoisomerase inhibitors
treatment
surgical adhesions
adhesions
surgical
Prior art date
Application number
AT01909384T
Other languages
English (en)
Inventor
John Jackson
Helen Burt
Stephen Dordunoo
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE407676T1 publication Critical patent/ATE407676T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01909384T 2000-02-28 2001-02-28 Topoisomerasehemmern zur behandlung von chirurgischen verklebungen ATE407676T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18556500P 2000-02-28 2000-02-28

Publications (1)

Publication Number Publication Date
ATE407676T1 true ATE407676T1 (de) 2008-09-15

Family

ID=22681523

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01909384T ATE407676T1 (de) 2000-02-28 2001-02-28 Topoisomerasehemmern zur behandlung von chirurgischen verklebungen

Country Status (7)

Country Link
US (1) US8883856B2 (de)
EP (2) EP1261337B1 (de)
JP (1) JP2003525243A (de)
AT (1) ATE407676T1 (de)
CA (1) CA2401340A1 (de)
DE (1) DE60135732D1 (de)
WO (1) WO2001064214A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002045D0 (sv) * 2000-05-31 2000-05-31 Sahltech Ab New use
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7074824B2 (en) 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6962944B2 (en) 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US8450071B2 (en) 2002-03-08 2013-05-28 The Board Of Regents Of The University Of Oklahoma Biomarker and method for detecting a chronic inflammatory-associated disease
US7655480B2 (en) * 2002-03-08 2010-02-02 The Board Of Regents Of The University Of Oklahoma Method for predicting sepsis or an acute infectious inflammatory response
WO2003076459A1 (en) * 2002-03-08 2003-09-18 Heloise, Anne, Pereira, Ph. D. An early detection marker for chronic inflammatory associated diseases
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
TWI353854B (en) * 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
US20050208101A1 (en) * 2002-07-23 2005-09-22 Viktor Sevastianov Coating composition for an implantable medical device and method for coating such a device
DE10234398B4 (de) * 2002-07-23 2006-07-27 Ls-Medcap Gmbh Beschichtungszusammensetzung für eine implantierbare medizinische Vorrichtung und Verfahren zur Beschichtung einer solchen Vorrichtung und seine Verwendung
US20040146546A1 (en) * 2002-09-26 2004-07-29 Angiotech Pharmaceuticals, Inc. Perivascular wraps
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
WO2005053682A2 (en) * 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
US20050250709A1 (en) * 2003-12-19 2005-11-10 Bionaut Pharmaceuticals Anti-neoplastic agents, combination therapies and related methods
US8828416B2 (en) * 2004-03-09 2014-09-09 Cordis Corporation Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury
US20070238677A1 (en) * 2004-03-17 2007-10-11 Locomogene, Inc. Pharmaceutical Composition Containing Hshrd3
EP1756571B8 (de) * 2004-04-09 2010-10-13 University of Pittsburgh - Of the Commonwealth System of Higher Education Verfahren in echtzeit zur erkennung von akuten entzündungszuständen
JP3953092B2 (ja) * 2004-04-27 2007-08-01 コニカミノルタオプト株式会社 対物レンズ及び光ピックアップ装置
EP1796688B1 (de) * 2004-09-02 2011-05-18 Bionaut Pharmaceuticals Inc Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern
US20070105790A1 (en) * 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
US20060135441A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors
US20060135468A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
WO2006063430A1 (en) * 2004-12-16 2006-06-22 Miv Therapeutics Inc. Multi-layer drug delivery device and method of manufacturing same
KR100752244B1 (ko) * 2005-02-16 2007-08-27 주식회사 엠디바이오알파 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 약제 조성물
CA2598213C (en) * 2005-02-18 2011-04-19 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
EP2494965A3 (de) 2005-04-15 2013-01-02 The Albert Einstein College Of Medicine Of Yeshiva University Vitamin K zur Vorbeugung und Behandlung von zur Behandlung mit Anti-EGF-Rezeptor sekundärem Hautausschlag
US20060275341A1 (en) * 2005-06-02 2006-12-07 Miv Therapeutics Inc. Thin foam coating comprising discrete, closed-cell capsules
WO2007016656A2 (en) * 2005-08-02 2007-02-08 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses for the treatment of ocular disorders
US9428582B2 (en) * 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
US20080051702A1 (en) * 2006-08-24 2008-02-28 Herrmann Robert A Therapeutic agent delivery for the treatment of asthma via implantable and insertable medical devices
KR20080047957A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 고혈압의 치료 및 예방을 위한 약제 조성물
US9399675B2 (en) 2007-02-28 2016-07-26 The Board Of Regents Of The University Of Oklahoma Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
US20120100218A1 (en) * 2008-01-30 2012-04-26 Laird Forrest Intralymphatic Chemotherapy Drug Carriers
EP2265126A4 (de) * 2008-03-10 2011-06-29 Univ Louisville Res Found Verfahren und zusammensetzungen für die kontrollierte abgabe von phytochemikalien
US8858995B2 (en) 2008-03-10 2014-10-14 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
US8815953B2 (en) 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
CA2738952A1 (en) * 2008-10-16 2010-04-22 Cypress Bioscience, Inc. Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases
CA2748296C (en) * 2008-12-23 2017-03-21 Surmodics Pharmaceuticals, Inc. Implantable composites and compositions comprising releasable bioactive agents
US8940705B2 (en) * 2009-01-09 2015-01-27 The Regents Of The University Of California Method of treating disease and selectively modulating transcriptional regulation by a glucocorticoid receptor by administering aclacinomycin and dexamethasone
CA2773552C (en) * 2009-09-15 2017-11-21 Csl Limited Treatment of neurological conditions
WO2011057286A1 (en) * 2009-11-09 2011-05-12 Drexel University Compositions and methods for treating a disorder or defect in soft tissue
US20120142650A1 (en) * 2010-12-07 2012-06-07 John Hollingsworth Method for treating lung disease
ES2622153T3 (es) * 2011-09-08 2017-07-05 Instituto De Medicina Molecular Una antraciclina para el tratamiento de la sepsis
US8877808B2 (en) * 2012-12-06 2014-11-04 Aurin Biotech Inc. Protection against skin diseases by aurin tricarboxylic acid and its derivatives
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
EP3393490A4 (de) 2015-12-15 2019-11-20 Icahn School of Medicine at Mount Sinai Verfahren zur behandlung einer verschlimmerten entzündungsreaktion mit topoisomerase-l-inhibitoren
EP3620531A4 (de) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
PL3630188T3 (pl) 2017-05-31 2022-01-03 Amplio Pharma Ab Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii
EP3651750A4 (de) 2017-07-14 2021-04-14 University of Massachusetts Verfahren und zusammensetzungen zur behandlung von entzündungen
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
MX2023003401A (es) 2020-10-08 2023-04-25 Curome Biosciences Co Ltd Composicion farmaceutica para prevenir o tratar enfermedad hepatica colestasica, que contiene beta-lapachona como ingrediente activo.
WO2022159730A1 (en) * 2021-01-22 2022-07-28 Icahn School Of Medicine At Mount Sinai Methods of treating lung inflammation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4114238B1 (de) * 1964-09-02 1966-08-09
DE2240187A1 (de) * 1972-08-16 1974-02-21 Jereb Franz Dr Albin Salbe
US4758587A (en) * 1987-03-09 1988-07-19 Syntex (U.S.A.) Inc. Naphthalene anti-psoriatic agents
US5763479A (en) * 1991-02-04 1998-06-09 Ks Biomedix Ltd. Naphthoquinone derivatives for the treatment of chronic inflammation
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
DE69435002T2 (de) * 1993-07-19 2008-03-20 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene Mittel enthaltend Taxol und einen nicht biodegradierbaren Träger und deren Verwendung
FR2725990B1 (fr) * 1994-10-21 1997-01-10 Pf Medicament Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US5736129A (en) * 1995-11-17 1998-04-07 Medenica; Rajko D. Flow cytometric pharmacosensitivity assay and method of cancer treatment
US5847003A (en) * 1996-06-04 1998-12-08 Avon Products, Inc. Oxa acids and related compounds for treating skin conditions
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
EP0990635B1 (de) * 1997-06-13 2003-09-17 Takara Bio Inc. Hydroxycyclopentanone
US6485514B1 (en) * 1997-12-12 2002-11-26 Supergen, Inc. Local delivery of therapeutic agents
WO1999063982A1 (en) * 1998-06-11 1999-12-16 University Of Medicine & Dentistry Of New Jersey Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
EP1087801B1 (de) 1998-06-26 2002-01-16 Quanam Medical Corporation Topoisomerase inhibitoren zur restenose-prevention
WO2000009071A2 (en) * 1998-08-11 2000-02-24 All India Institute Of Medical Sciences A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
US6187822B1 (en) 1999-06-11 2001-02-13 University Of Medicine & Dentistry Of Nj Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin

Also Published As

Publication number Publication date
EP1261337A2 (de) 2002-12-04
EP2000136A3 (de) 2008-12-31
WO2001064214A3 (en) 2002-05-10
EP2000136A2 (de) 2008-12-10
CA2401340A1 (en) 2001-09-07
US20030139353A1 (en) 2003-07-24
US8883856B2 (en) 2014-11-11
WO2001064214A2 (en) 2001-09-07
DE60135732D1 (de) 2008-10-23
EP1261337B1 (de) 2008-09-10
JP2003525243A (ja) 2003-08-26

Similar Documents

Publication Publication Date Title
ATE407676T1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE247117T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
DK1313740T3 (da) Prodrugs af imidazopyridinderivater
DE60326069D1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
TR200200278T2 (tr) Kalsilitik bileşimler
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE381568T1 (de) Pyrano(2,3-c)imidazo(1,2-a)pyridin-derivate zur behandlung von gastrointestinalen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties